|
 |
NamendaThis page contains recent news articles, when available, and an overview of Namenda but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Namenda (when available) Memantine is an orally active NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that Memantine prevents or slows neurodegeneration in patients with Alzheimer's disease. For the treatment of moderate to severe dementia of the Alzheimer's type. Mechanism Of Action: Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells and ultimately neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. News Articles on Memantine 抗è€?年性痴呆用è?¯å¸‚场充满生机 - 05 Jan 2010 ...çš„å?¡å·´æ‹‰æ±€(Exelon)ã€?美国强生公å?¸å¼€å?‘çš„åŠ å…°ä»–æ•?(Razadyne)ã€?美国森林制è?¯å…¬å?¸å¼€å?‘çš„ç›?酸他克林(Cognex)ã€?森林制è?¯å’Œä¸¹éº¦ç?µåŒ—å…¬å?¸ä¸Šå¸‚çš„ç›?酸美金刚(Namenda)。 ... 中国化工网 Lupin Settles Litigation With Forest For Namenda Tablets - Dec 22, 2009 While the settlement means Lupin can launch Memantine--the generic version of Namenda--before Forest's patent expires in April 2015, analysts say it's too ... Wall Street Journal Congress Punts on the Estate Tax - Dec 18, 2009 Namenda, for Alzheimer's, grosses 27% of sales, or about $1.1 billion. Lexapro's patent will expire in 2012 and Namenda's in 2015. ... TheStreet.com Indian Market Seen Opening Flat - Dec 22, 2009 ...litigation with multinational Forest Laboratories relating to its US launch of memantine tablets, the generic version of Forest Lab's Namenda tablets. ... RTT News Soleil Securities Initiates Coverage on Forest Laboratories (FRX) with a Buy - Dec 18, 2009 ...leaving room for cost initiatives to drive increased valuation, until the patent cliffs for Lexapro (Mar 2012) and Namenda (April 2015). ... StreetInsider.com (subscription) Indian stock market and companies daily report (December 23, 2009, Wednesday) - Dec 22, 2009 Forest Labs sells the drug, used to treat Alzheimer's Syndrome, under the brand name Namenda. Namenda tablets generated sales of US $949mn in CY2008. ... Stock Markets Review Closing Bell - Dec 22, 2009 Inc.'s Alzheimer disease treatment Namenda tablets. As per the terms of the settlement, Lupin will be licensed under the relevant patents and would be free ... Economic Times Banks, IT buoy markets - Dec 22, 2009 Forest Labs sells the drug under the brand name Namenda. The company generated sales of US$ 949 m from this drug in the year 2008 and it accounted for 26% ... Equitymaster.com India Stocks Surge; Outlook Revised to 8% - Dec 23, 2009 Laboratories Inc. and can launch its generic version of the company''s Namenda tablets by January 2015, or earlier depending on certain conditions. ... 123Jump.com Forest Laboratories Inc (NYSE:FRX) to Hold Analyst and Investor Webcast - Dec 15, 2009 ...the Company's selective serotonium reuptake inhibitor (SSRI) for the treatment of major depression and generalized anxiety disorder (GAD); Namenda, ... TransWorldNews (press release) Look for Novartis-Alcon deal in early 2010; Sealed Prempro verdict levies $8M ... - Dec 23, 2009 ...has reached an out-of-court settlement with Forest Laboratories and can launch its generic version of the US company's Namenda tablets by January 2015. ... FiercePharma CORRECT: Forest Labs 2Q Net Drops 23% On Charges - Oct 20, 2009 The correct version follows: ) Forest Laboratories Inc.'s (FRX) fiscal second-quarter profit fell 23% on acquisition-related charges as sales of its Namenda ... Wall Street Journal Sun to stop making Alzheimer's drug after losing patent battle - Oct 23, 2009 Forest Lab's patent for Namenda expires in 2010, but the company has submitted an application to extend it till 2013. Bino Pathiparampil, vice-president ... Economic Times Nibbles Here and There at Forest Labs - Oct 22, 2009 Forest relies on two products for nearly 90% of its revenue -- the antidepressant Lexapro and the Alzheimer's disease drug Namenda. ... Motley Fool Axona, A Medical Food for Alzheimer's Disease - Nov 12, 2009 There were no significant interactions noted with commonly used Alzheimer's drugs, including donepezil (Aricept) or memantine (Namenda). ... eMaxHealth Forest Laboratories, Inc. - SWOT Analysis - Aarkstore Enterprise - Oct 30, 2009 The increase was mainly due to the strong sales of Lexapro and Namenda. The operating profit of the company was $708.8 million during fiscal year 2007, ... PRMinds (press release) Forest Laboratories Inc. F2Q10 (Qtr End 30/09/09) Earnings Call Transcript - Oct 20, 2009 Lexapro sales remain close to target, despite the expected modest decrease in market share, and we saw continued solid prescription growth for Namenda, ... Seeking Alpha (blog) Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate ... - Nov 4, 2009 ...as primary endpoints the effects of adding dimebon to Namenda®, a standard of care Alzheimer's disease medicine, on cognitive and behavioral symptoms. ... Reuters HOME PAGE - Nov 3, 2009 It is marketed under the brand name Namenda by the firm Forest Pharmaceuticals Inc. A few small trials have suggested it could be useful for children with ... San Jose Mercury News US HOT STOCKS: SanDisk, Yahoo, Cree Active In Late Trading - Oct 20, 2009 Forest Laboratories Inc.'s (FRX, $28.96, -$1.29, -4.26%) fiscal second-quarter profit fell 23% on acquisition-related charges as sales of its Namenda ... Wall Street Journal Investment Thesis for Forest Laboratories, Inc. (FRX) - Nov 10, 2009 ...the Company's selective serotonium reuptake inhibitor (SSRI) for the treatment of major depression and generalized anxiety disorder (GAD); Namenda, ... GuruFocus.com Local Alzheimer's Patients See Benefits From Food - Oct 30, 2009 Dr. Crumpacker says there are a handful of medications for Alzheimer's patients like Aricept and Namenda that help replace certain chemicals in the brain to ... CBS 11 Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per ... - Oct 20, 2009 Namenda, an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer`s disease, recorded sales of $275.3 million during the quarter, ... Reuters Sun Pharma to Cease Manufacturing Generic Alzheimer's Drug - Oct 28, 2009 Forest's patent for Namenda expires in 2010. However, Forest Laboratories has filed an application to extend its Alzheimer's drug patents until 2013, ... istockAnalyst.com (press release) Zacks Analyst Blog Highlights: Biogen Idec, Elan, UnitedHealth Group Inc ... - Oct 22, 2009 Although Lexapro sales declined 3.1% to $566 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer's disease, ... Business Wire (press release) êµ?린, ë©”ë¥´ì¸ ì?´ëª…ì¹˜ë£Œì œ '네ë?¼ë©•ì‚°' ë?„ìž… - Nov 9, 2009 ...ë©”ë¥´ì¸ ëŠ” ì•Œì¸ í•˜ì?´ë¨¸ë³‘ ì¹˜ë£Œì œ '나멘다'(Namenda, memantine)를 개발한 기업으로 잘 ì•Œë ¤ì ¸ 있으며 네ë?¼ë©•ì‚°ì?€ 현재 미êµê³¼ ìœ ëŸ½ì—?ì„œ 3ìƒ? ìž„ìƒ?시험 중ì?´ë‹¤. 디지틀보사 Forest Labs第二财å£ç›ˆåˆ©ä¸‹é™?24% - Oct 20, 2009 Forest表示，Lexapro的销售é¢?下é™?3%，至5.66亿美元，但阿尔兹海默症è?¯ç‰©Namenda的销售é¢?增长12%，至2.75亿美元。一年å‰?上市的高血压è?¯ç‰©Bystolic的销售é¢?增长将近两 ... 新浪网 Forest Laboratories muss Gewinnrückgang ausweisen - Oct 20, 2009 Unter anderem waren die Umsatzerlöse beim Antidepressivum Lexapro um 3,1 Prozent gesunken, während man beim Alzheimer-Medikament Namenda einen Umsatzanstieg ... FinancialLife Barr Pharma initiates patent challenge to Forest Labs' Namenda - Jan 11, 2008 SAN FRANCISCO (Thomson Financial) - Barr Pharmaceuticals Inc. on Friday confirmed that its subsidiary, Barr Laboratories Inc., has initiated a challenge of ... Forbes Generics seek to market version of Forest's Namenda - Dec 13, 2007 NEW YORK, Dec 13 (Reuters) - Forest Laboratories Inc (FRX.N) said on Thursday it received notice that several companies are seeking to market a generic ... Reuters Forest Labs profit beats Street as Namenda soars - Oct 21, 2008 NEW YORK NEW YORK, Oct 21 (Reuters) - Forest Laboratories Inc posted higher-than-expected quarterly profit on Tuesday, fueled by stronger sales of its drugs ... Forbes Forest Turns In Fairish Results - Jan 17, 2006 ...$427.1 million for the year-ago period, and the Alzheimer's disease drug Namenda, whose sales rose to $124 million from $100.6 million last year. ... TheStreet.com - TheStreet.com (subscription) FDA Deals Forest Labs a Setback - Jul 25, 2005 Although Namenda is the only product approved in the US for moderate to severe ... Namenda was approved for treating moderate to severe forms of the disease ... TheStreet.com - TheStreet.com (subscription) Forest Labs posts loss on acquisition charge - Apr 24, 2007 Sales of the company's Namenda drug for Alzheimer's disease increased 24 percent to $179.7 million. Forest took a charge of $476 million, or $1.49 per share ... Reuters Competition Hits Forest Labs' Sales - Jul 19, 2005 Most of the company's sales came from two drugs -- the antidepressant Lexapro ($461 million) and the Alzheimer's disease drug Namenda ($114.7 million). ... TheStreet.com - TheStreet.com (subscription) Forest Labs: Alzheimer's drug effective - Feb 5, 2008 Namenda, also called memantine HCl, is already approved as a twice-daily, 10-milligram ... Namenda is the first in a class of medications which focus on the ... Forbes COMPANY EARNINGS, Bad, good for Forest Labs - Jul 19, 2006 The increase was fueled by sales of blockbuster antidepressant Lexapro, which grew 10 percent to $507 million, and sales of Namenda for Alzheimer's, ... Pay-Per-View - Newsday - ProQuest Archiver Lexapro, Namenda boost Forest - Jan 15, 2008 Who does Forest Labs appreciate? Lexapro and Namenda, to name two. The two drugs helped boost the drug maker's fiscal third-quarter net by 21 percent to ... FiercePharma Forest net falls, sales miss Wall Street view - Oct 16, 2007 Sales of its Namenda Alzheimer's disease drug climbed 24 percent to $193 ... Forest is trying to shore up its product line before Lexapro and Namenda lose ... Reuters Forest Net Rises on Antidepressant, Alzheimer's Drug - Oct 17, 2006 Sales jumped 12 percent for Lexapro and 26 percent for Namenda, ... Sales of Lexapro climbed to $522.7 million, while Namenda reached $155.6 million. ... Bloomberg Danish shares flat midmorning; Jyske Bank up on H1, Lundbeck dn on … - Jul 26, 2005 Lundbeck markets Namenda as Ebixa. Novo Nordisk added 0.5 to 313 and Novozymes was 1 higher at 308. TDC was 1 lower at 267 on concern that Vodafone may ... Forbes Antidepressant Sales Bolster Profit at Forest Laboratories - Jan 17, 2007 Sales of Namenda rose to $173.9 million, from $124 million. “A key reason Lexapro outperformed expectations was that investor fears that generic Zoloft ... New York Times Forest Labs, Merz file 2nd patent suit - Jan 25, 2008 New York-based Forest has claimed its patent for Namenda does not expire until April 2010, and that it is seeking patent extension approval through ... Boston Globe Forest Labs reports lowered earnings - Oct 18, 2005 Sales of the drugmaker's Alzheimer's drug Namenda more than doubled to $123.9 million. Lexapro also faces a generic challenge. On Dec. ... MarketWatch Namenda(R) Slows Severe Alzheimer's Symptoms For One Year, Follow- … - Jan 10, 2006 A drug used to treat symptoms of moderate to severe Alzheimer's disease appears to be effective for one year, according to the results of a new multicenter ... Medical News Today - Medical News Today (press release) Forest Labs quarterly profit falls - Jul 22, 2008 N) reported lower quarterly profit on Tuesday as higher sales and administrative costs offset stronger sales of its Lexapro antidepressant and Namenda ... Reuters UK Forest Labs quarterly profit up 34 pct - Jul 17, 2007 Forest's shares have fallen about 10 percent this year despite the generally strong performance of Lexapro and Alzheimer's drug Namenda. ... Reuters Forest Beats, Guides In Line - Jan 18, 2005 Sales growth for Lexapro and other products, such as Namenda for Alzheimer's disease, "will serve to overcome the loss of Celexa revenues during the coming ... TheStreet.com - TheStreet.com (subscription) Forest profit beats, but outlook sluggish - Apr 15, 2008 Sales of Alzheimer's treatment Namenda climbed 26 percent to $179.7 million. ... Forest is trying to build up its product line before Lexapro and Namenda ... Reuters Forest Labs to Keep Studying Alzheimer's Drug - Jul 14, 2005 It already sells Namenda, a member of the same class of drugs as neramexane, for patients with moderate to severe Alzheimer's disease. ... TheStreet.com - TheStreet.com (subscription) Forest Labs Guides Higher - Jan 4, 2005 ...as generic competition began to take its toll. Sales of Namenda, for treating moderate to severe Alzheimer's disease, were approximately $100 million. TheStreet.com - TheStreet.com (subscription) New Data Highlights Positive Results Of Namenda(R) (Memantine HCl) … - Aug 1, 2008 Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda® (memantine HCl) at the 2008 ... Medical News Today - Medical News Today (press release) Namenda.(drug overview)(Drug overview) - Dec 1, 2005 Namenda is a new kind of medication used for treating moderate to severe Alzheimer's disease. While other Alzheimer's drugs work to prevent the breakdown of ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Namenda for Migraine and Chronic Headache Prevention - Nov 3, 2007 There are no medications available that were developed for the purpose of Migraine and headache prevention. However, there are over 100 medications that are ... HealthCentral.com Forest Sues to Protect Namenda Patent - Jan 21, 2008 Forest Laboratories and Merz Pharma have launched lawsuits against several generic firms seeking approval to market generic Namenda before the expiration of ... FDA news - FDA news (subscription) Follow-up Study Shows Drug Slows Severe Alzheimer's Symptoms For … - Jan 27, 2006 Namenda® was approved in October 2003 by the Food and Drug Administration for the ... Forest Pharmaceuticals Inc sells Namenda® in the United States. ... sciencedaily.com Barr Pharmaceuticals confirms patent challenge of Namenda tablets - Jan 14, 2008 Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories ... News-Medical.net Event Brief of Q4 2006 Forest Laboratories, Inc. Earnings Conference... - Apr 25, 2006 Namenda has continued to generate increased prescription volume largely driven by an ... Namenda sales totaled $145.4m, an increase of 55% from 4Q05. 2. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Namenda for Migraine and Chronic Headache Prevention - Nov 3, 2007 There are no medications available that were developed for the purpose of Migraine and headache prevention. However, there are over 100 medications that are ... HealthCentral.com … announces FDA nonapprovable letter on sNDA for Namenda for mild AD - Aug 23, 2005 Namenda was approved by the FDA for the treatment of moderate-to-severe Alzheimer ... Nevertheless, the FDA decided not to approve Namenda for mild patients ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones New Data Highlight Positive Results Of Namenda(R) (memantine HCl) … - Jul 31, 2008 Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the ... Medical News Today - Medical News Today (press release) Pal's pet licks dishes? Suggest a restaurant - Feb 24, 2007 The doctor has started her on Namenda and Lexapro. Any information you can share with me will ... Namenda is for dementia, and Lexapro is an antidepressant. ... Youngstown Vindicator Behavior Problems in Moderate to Severe Alzheimer's Disease Improved ... - Oct 10, 2006 Namenda is manufactured by Forest Laboratories, Inc., which sponsored the study. [Presentation title: NPI Subscale Analysis of Memantine/Donepezil Treatment ... DG News Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral … - Aug 18, 2005 NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. announced today that an oral solution formulation of Namenda(R)(memantine HCl), ... $4.95 - PR Newswire - ECNext Alzheimer's Disease - Medications - Nov 10, 2008 ...who took cholinesterase inhibitors experienced improvement in thinking and daily functioning when they added memantine (Namenda) to their treatment. 10 ... WebMD Drug holds back Alzheimer's disease - Jan 19, 2006 Namenda® is the only drug that is approved for later stage Alzheimer's disease. ... Clearly Namenda can bring important benefits to those with moderate to ... HealthandAge.com Press Release: Oral Solution Formulation of Namenda(R), the Only FDA-... - Aug 18, 2005 Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Available. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research The age of Alzheimer's: while a cure for Alzheimer's disease seems … - Aug 1, 2006 Forest Pharmaceuticals' Namenda is Aricept's biggest competitor. Since approval in October 2003, Namenda quickly grabbed 23% market share (Fig. ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Alzheimer Disease; Oral solution formulation of Namenda available … - Sep 19, 2005 2005 SEP 19 - (NewsRx.com) -- Forest Laboratories, Inc., (FRX) announced that an oral solution formulation of Namenda (memantine HCl), the only US Food and ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Dementia versus Alzheimer's - Nov 28, 2007 At present, there are several medications on the market, such as Aricept and Namenda. However, significant improvements in patients' mental abilities are ... $2.95 - Erie Times-News - NewsBank Chattanooga: Costly medicines prompt some to question Alzheimer's … - Oct 20, 2008 Another common Alzheimer's medicine is Namenda, which regulates the activity of glutamate, another body chemical involved in learning and memory. ... Chattanooga Times Free Press Dear Pharmacist: Spices Can Do More Than Flavor Your Food - Mar 7, 2006 ...that it can slow the progression of Alzheimer's disease, but there are no studies yet comparing it to drugs such as Namenda, Exelon, Reminyl or Aricept. ... RedOrbit FDA Approvals: Aceon, 0.1% Alphagan P, Namenda Oral Solution - Aug 25, 2005 Aug. 25, 2005 — The US Food and Drug Administration (FDA) has approved once-daily perindopril erbumine tablets for use alone or in combination with ... Medscape Q2 2006 Forest Laboratories, Inc. Earnings Conference Call - Part 1. - Oct 1, 2005 However, sales of Lexapro and Namenda totaled $591 million in the quarter, ... Looking now at Namenda, the product continued to make gains in total ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com ALSO NOTED: Forest sues generics over Namenda; Omrix gets new … - Jan 11, 2008 ...> Forest Labs and Merck KGaA are suing several generics makers--including Barr, Cobalt, Lupin, Orchid, Teva, and Wockhardt--for infringing patents on the ... FiercePharma Dementia.(Behavioral Health Advisor 2007)(Disease/Disorder overview) - May 31, 2007 Memantine (Namenda) may help slow memory loss in later stages of the disease. Vitamin E and other medicines continue to be studied to see whether they might ... $4.95 - Clinical Reference Systems - ECNext Namenda solution wins FDA approval.(Forest Laboratories Inc., Food... - Sep 1, 2005 THE FDA approved an oral solution formulation of Forest Laboratories' Namenda (memantine hydrochloride).The oral solution offers an alternative for patients ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com Dementia.(Behavioral Health Advisor 2006)(Disease/Disorder overview) - Nov 1, 2006 Memantine (Namenda) may help slow memory loss in later stages of the disease. Vitamin E and other medicines continue to be studied to see whether they might ... $4.95 - Clinical Reference Systems - ECNext … : New Data Highlight Positive Results of Namenda(R) (memantine HCl)... - Jul 30, 2008 New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Lexapro and Namenda help Forest's income for fiscal 3rd-qtr soar 21%,... - Jan 21, 2008 US drugmaker Forest Laboratories says that higher sales helped boost earnings in its fiscal third quarter ended December 2007. Net income increased 21% to ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Memantine (Namenda) Effective for Behavioral Symptoms in Patients … - May 31, 2005 By Bruce Sylvester. ATLANTA, GA -- May 31, 2005 -- Memantine (Namenda) appears to be effective in treating mild to moderate Alzheimer's, ... DG News Forest Laboratories Expects Lower Earnings - Apr 6, 2005 Sales of Namenda amounted to approximately $93 million in the fiscal fourth quarter compared to $100 million in the fiscal third quarter. ... WebProNews … Release: Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg... - Jan 11, 2008 Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Alzheimer's disease.(disease overview)(Disease/Disorder overview) - May 24, 2006 Other medicines, such as memantine (Namenda), may help slow memory loss in later stages of the disease. These drugs are costly and have side effects. ... $4.95 - Clinical Reference Systems - ECNext Forest Laboratories Reports Earnings Per Share of .59 for Q2'06 -... - Oct 18, 2005 Sales of Namenda(R), an NMDA receptor antagonist for the treatment of ... Namenda and Benicar continued to exhibit strong performance during the quarter. ... RedOrbit Namenda solution wins FDA approval.(Forest Laboratories Inc., Food... - Sep 1, 2005 Namenda solution wins FDA approval.(Forest Laboratories Inc., Food and Drug Administration)(Brief Article) ... find Medical Marketing & Media articles. Pay-Per-View - Medical Marketing & Media - HighBeam Research Eisai: Aricept in for Severe Approval - Sep 5, 2005 However, Forest's Namenda is currently the only drug approved for severe AD. ... The supplemental new drug application (sNDA) for Namenda in mild to ... RedOrbit FDA clears oral form of Forest's AD drug Namenda.(Food and Drug … - Aug 29, 2005 Forest Laboratories of the USA says that the US Food and Drug Administration has approved the oral formulation of its Alzheimer's disease product Namenda ... $4.95 - Pharma Marketletter - ECNext … FDA Decision on Supplemental New Drug Application for Namenda(R). - Jul 25, 2005 Namenda was approved by the FDA for the treatment of moderate to severe Alzheimer's disease in ... Namenda, introduced in December 2003, was by far the ... ... Pay-Per-View - PR Newswire - HighBeam Research Forest Laboratories, Inc. at Deutsche Bank Securities Inc. Health... - May 3, 2005 The Company also has a fast-growing drug in Namenda, the first product approved for moderate to severe Alzheimer's disease and anti-hypertensive drug, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Finance; Namenda maker to exceed fiscal 2005 Q3 mean earnings per … - Feb 1, 2005 2005 FEB 1 - (NewsRx.com & NewsRx.net) -- Forest Laboratories, Inc., (FRX), an international pharmaceutical manufacturer and marketer, announced that it ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Forest Laboratories, Inc. Announces Positive Results Of Memantine... - Feb 6, 2008 The recommended dose for Namenda is currently 10 mg two times a day (20 mg/day), ... Namenda is currently available in tablets or liquid form. ... Medical News Today - Medical News Today (press release) Alzheimer Disease; Enrollment ends in proof-of-concept clinical study... - Oct 25, 2005 The study protocol prohibited the concomitant use of Namenda (memantine), a recently approved treatment for Alzheimer disease which was commercialized after ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Corcept Closes Enrollment of Proof of Concept Clinical Study Evaluatin... - Sep 26, 2005 The study protocol prohibited the concomitant use of Namenda (memantine), a recently approved treatment for Alzheimer's disease which was commercialized ... $4.95 - PR Newswire - ECNext Memory Clinic seeks Alzheimer's patients for tests - May 2, 2005 Patients may be taking Aricept, Exelon, Reminy, or Namenda and still participate, said Solomon. Patients and caregivers who would like more information ... $2.95 - Berkshire Eagle, The - NewsBank Aricept and Aciphex lead Eisai's growth.(Brief Article) - Aug 15, 2005 They were 32.7% higher at $219.0 million in the USA, where the product encountered less competitive pressure from Forest Laboratories' Namenda (memantine), ... $4.95 - Pharma Marketletter - ECNext The Age of Alzheimer's - Aug 1, 2006 Forest Pharmaceuticals' Namenda is Aricept's biggest competitor. Since approval in October 2003, Namenda quickly grabbed 23% market share (Fig. ... Medical Marketing & Media - Medical Marketing and Media Lundbeck siver pÃ¥ svagere Lexapro-salg - Oct 16, 2007 Han bemærker, at Namenda - til behandling af alzheimers-sygdom - viste overraskende gode salgstakter med en vækst pÃ¥ 24 pct. til 192,9 mio. dollar i ... Børsen Online Federal Register 2007 - 72 FR 31075 Determination of Regulatory … - Jun 5, 2007 FDA recently approved for marketing the human drug product, NAMENDA Page 31076 ... NAMENDA is indicated for the treatment of moderate to severe dementia of ... Pay-Per-View - Federal Register 2007 - Loislaw Q1 2008 Forest Laboratories, Inc. Earnings Conference Call - Final. - Jul 17, 2007 Moving to Namenda, the brand's performance has remained strong, largely driven ... This is reflected in the expansion in the overall use of the Namenda in ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com TWO MEDICATIONS CAN SLOW RATE OF DEMENTIA - Dec 1, 2005 Namenda, another effective drug, helps to regulate the neurotransmitter glutamate. ... Namenda is believed to work by attaching to nerve receptors that ... Pay-Per-View - Daily Press - ProQuest Archiver Finansfokus - tirsdag (Gent) - Oct 21, 2008 Forest Laboratories sidder ogsÃ¥ pÃ¥ rettighederne til salget af Namenda, ... Ebixa er Lundbecks navn for Namenda. Før amerikanske Ã¥bningstid er de ... Fyens Stiftstidende Forest Laboratories Inc. - Jun 19, 2006 FRX's second most important product is Namenda (licensed from Merz Pharmaceuticals of ... In March 2006, Namenda accounted for about 30% of the prescription ... $35.00 - Stock Reports - Standard & Poor's … Notification of ANDA Filings for Generic Equivalents of Namenda(R). - Dec 13, 2007 Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research תביעה משפטית × ×’×“ טבע על הפרת ×¤×˜× ×˜ לתרופת ×”-Namenda ל×?לצהיימר - Jan 11, 2008 ...בתביעה פורסט ×˜×•×¢× ×ª, ×›×™ ×”×¤×˜× ×˜ על ×”-Namenda ל×? ... תרופה ×”-Namenda ×”×™× ×” בעלת היקף המכירות ×”×©× ×™ ... Bizportal Lundbeck/Forest: Positive fase III-resultater af Namenda (Opd.) - Feb 5, 2008 De foreløbige resultater af et fase III-studie med Alzheimer-midlet Namenda i en ny formular, hvor midlet kun skal tages en gang dagligt, viser positive ... UgensErhverv Lundbeck: Forest-salg af Lexapro steget 9 pct. (Opdat) - Jul 17, 2007 De to Lundbeck-midler Lexapro og Namenda har bidraget betydeligt til ... Samtidig er salget af Lundbecks Alzheimers-middel Namenda øget med 27 pct. til 192 ... UgensErhverv Event Brief of Q2 2007 Forest Laboratories, Inc. Earnings Conference... - Oct 17, 2006 Namenda: 1. The brand has continued to generate increased prescription ... This was reflected in the continued expansion and overall use of Namenda in ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Forest Labs Outlook Disappoints - Oct 6, 2005 Forest continues to talk to the Food and Drug Administration about expanding the use of the Alzheimer's disease drug Namenda, Goodman said. ... TheStreet.com - TheStreet.com (subscription) Aktier: Fald efter endnu en hÃ¥rd uge - Jan 11, 2008 ...roducenterne har søgt om godkendelse af kopi-Namenda hos de amerikanske myndigheder, men Forest mener, at Alzheimers-midlet Namenda er dækket af ... DR Q3 2007 Forest Laboratories, Inc. Earnings Conference Call - Part 1. - Jan 1, 2007 Moving on to Namenda, the brand has continued to generate increased ... This is reflected in the continued expansion and overall use of Namenda in ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com IN BRIEF - Jul 26, 2005 Forest Laboratories said yesterday that the Food and Drug Administration had declined to approve an additional use for the drug Namenda, which now treats ... Pay-Per-View - Newsday - ProQuest Archiver ìœ ì½”í”¼ì•„ - 바로 ì?´ 순간ì?˜ 미êµì?´ í•œêµì–´ë¡œ 펼ì³?집니다. - Aug 8, 2007 ...ê·¸ë?™ì•ˆ ì•Œì¸ í•˜ì?´ë¨¸ ì¹˜ë£Œì œëŠ” í™”ì?´ì €(Pfizer)사ì?˜ 아리셉트(Aricept), 노바티스(Novartis) 사ì?˜ ì—‘ì…€ë¡ (Exelon), í?¬ë ˆìŠ¤íŠ¸ ëž©(Forest Labs)ì?˜ '나멘다'(Namenda) 등ì?´ ... ìœ ì½”í”¼ì•„ NICE: limiti all'impiego dei farmaci anti-Alzheimer - Feb 8, 2007 ...del Donepezil ( Aricept ), Galantamina ( Reminyl ), Rivastigmina ( Exelon ) e Memantina ( Namenda / Ebixa ) nel trattamento della malattia di Alzheimer. ... XagenaSalute Press Release: FDA Approves Expanded Use of Treatment for Patients … - Oct 23, 2006 Forest expects Namenda ... treatment of moderate to severe Alzheimer's disease. ... Article: Namenda(TM) Shows Benefit in Behavioral Disturbances Associated ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Forest Laboratories, Inc. and Merz Pharma GmbH & Co. … - Jan 10, 2008 Article: Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg. ... Article: Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... ... Pay-Per-View - PR Newswire - HighBeam Research Forest Laboratories, Inc. Reports Fiscal First Quarter 2006 Results. - Jul 19, 2005 Namenda(R), our NMDA receptor antagonist for the treatment of moderate to severe ... Namenda continues to experience increases in the number of physicians ... $4.95 - PR Newswire - ECNext The trial will go well, but what are we trying to achieve? - Dec 28, 2008 Will it be more effective than the current meds here in the US(Aricept, Namenda, etc)? I have seen a fair number of Alzheimer pts who on Aricept have ... Gerson Lehrman Group Decreased Funding Causes Slow Progress in Alzheimer's Research - Feb 21, 2008 Correction: KPBS incorrectly identified memantine or Namenda as the ... In fact, Namenda is the most recent drug to be approved by the FDA for Alzheimer's. ... KPBS Event Brief of Q1 2008 Forest Laboratories, Inc. Earnings Conference... - Jul 17, 2007 Namenda: 1. Brand's performance has remained strong, largely driven by continued ... This is reflected in the expansion and the overall use of Namenda in ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com COMPANY EARNINGS, Losses afoot for Langer, Deer Park maker of … - Aug 10, 2006 Forest said strong sales of its Lexapro antidepressant and Namenda, ... The company said it anticipates continued growth of Namenda through fiscal 2007. ... Pay-Per-View - Newsday - ProQuest Archiver Ny Lundbeck-retssag pÃ¥ vej - Dec 14, 2007 Denne gang er det retten til Alzheimers-midlet Namenda, der stÃ¥r for skud, ... Namenda er dækket af patentrettigheden frem til april 2010 og retten kan ... TV2 Article: Drug improves severe Alzheimer's symptoms. - Healthy Years |... - Oct 1, 2007 Forest expects Namenda ... approved for the treatment of moderate to severe ... Article: Namenda(TM) Shows Benefit in Behavioral Disturbances Associated . ... Pay-Per-View - Healthy Years - HighBeam Research Paion, Forest stroke drug fails, deaths seen - May 31, 2007 Forest, a mid-sized US drugmaker, is profiting from the strong performance of its Lexapro antidepressant and Namenda Alzheimer's disease treatment. ... Reuters Forest Laboratories Reports Earnings Per Share of $0.71 for Q2'08 … - Oct 16, 2007 Namenda(R), our NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, recorded sales of $192872000 during the quarter, ... Free with registration - PR Newswire - AccessMyLibrary.com Ruby Washington/The New York Times - Jun 10, 2007 In one study of people taking Namenda and Aricept combined for six months, 60 percent of patients either improved or did not deteriorate. ... New York Times Danish shares close higher, led up by Novozymes, Danisco, Lundbeck … - Jul 17, 2007 The bank said the US sales growth in Namenda/Ebixa underlines a strong product profile and supports Sydbank's expectations of high growth in Ebixa sales. ... Forbes Gurus Buy Banks And Big Macs - Dec 8, 2008 ...with patent protection on its two principal products, antidepressant Lexapro and Alzheimer's treatment Namenda, expiring in 2012 and 2013. ... Forbes Brand Names/Synonyms: Namenda is also known by the following brand names and/or synonymsCHEMBANK733; D 145; D-145; DMAA; DRG 0267; DRG-0267; Ebixa; M183; M9292; MEMANTINE HYDROCHLORIDE; Memantina; Memantina [Inn-Spanish]; Memantine; Memantine Hydrochloride; Memantine [Inn]; Memantinum [Inn-Latin]; Namenda Drug Category: Namenda is categorized under the following by the FDA: Dopamine Agents; Antiparkinson Agents; Antidyskinetics; Excitatory Amino Acid Antagonists; Central Nervous System Agents; ATC:N06DX01 Dosage Forms: TABLET Absorption: Well absorbed orally, peak plasma concentrations are reached in 3-7 hours Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 3,5-dimethyladamantan-1-amine |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
